Literature DB >> 34877672

Advances in ameliorating inflammatory diseases and cancers by andrographolide: Pharmacokinetics, pharmacodynamics, and perspective.

Jiao Qu1, Qianqian Liu1, Guoquan You1, Ling Ye2, Yiguang Jin3, Lingdong Kong1, Wenjie Guo1, Qiang Xu1,4, Yang Sun1,4,5.   

Abstract

Andrographolide, a well-known natural lactone having a range of pharmacological actions in traditional Chinese medicine. It has long been used to cure a variety of ailments. In this review, we cover the pharmacokinetics and pharmacological activity of andrographolide which supports its further clinical application in cancers and inflammatory diseases. Growing evidence shows a good therapeutic effect in inflammatory diseases, including liver diseases, joint diseases, respiratory system diseases, nervous system diseases, heart diseases, inflammatory bowel diseases, and inflammatory skin diseases. As a result, the effects of andrographolide on immune cells and the processes that underpin them are discussed. The preclinical use of andrographolide to different organs in response to malignancies such as colorectal, liver, gastric, breast, prostate, lung, and oral cancers has also been reviewed. In addition, several clinical trials of andrographolide in inflammatory diseases and cancers have been summarized. This review highlights recent advances in ameliorating inflammatory diseases as well as cancers by andrographolide and its analogs, providing a new perspective for subsequent research of this traditional natural product.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  andrographolide; drug delivery system; inflammatory diseases; pharmacodynamics; pharmacokinetics

Mesh:

Substances:

Year:  2021        PMID: 34877672     DOI: 10.1002/med.21873

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  3 in total

1.  Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease.

Authors:  Li-Sha Ran; Ya-Zeng Wu; Yi-Wen Gan; Hong-Lian Wang; Li-Juan Wu; Chun-Mei Zheng; Yao Ming; Ran Xiong; Yong-Lin Li; Shi-Hang Lei; Xue Wang; Xiao-Qing Lao; Hong-Min Zhang; Li Wang; Chen Chen; Chang-Ying Zhao
Journal:  J Nat Med       Date:  2022-09-17       Impact factor: 3.192

2.  Identification of Immune-Related Gene Signature and Prediction of CeRNA Network in Active Ulcerative Colitis.

Authors:  Mengmeng Xu; Ying Kong; Nannan Chen; Wenlong Peng; Ruidong Zi; Manman Jiang; Jinfeng Zhu; Yuting Wang; Jicheng Yue; Jinrong Lv; Yuanyuan Zeng; Y Eugene Chin
Journal:  Front Immunol       Date:  2022-03-22       Impact factor: 7.561

Review 3.  Real-World Evidence of Traditional Chinese Medicine (TCM) Treatment on Cancer: A Literature-Based Review.

Authors:  Linjia Peng; Ke Zhang; Yujie Li; Lianyu Chen; Huifeng Gao; Hao Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.